You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Interleukin said in July that it would liquidate its assets after laying off 63 percent of its workforce and suspending sales of its controversial genetic test.
With new gene sequencing panels, investigators made firm or possible diagnoses in almost one-third of undiagnosed autoinflammation and vasculitis cases.
The announcement comes three weeks after Interleukin said it was laying off 63 percent of its workforce and suspending sales of a controversial genetic test.
The decisions are part of the company's restructuring efforts after it was unable to extend deferral of its debt payment with its senior lender.
In Genome Biology this week: parainflammation found in some cancers, recurrent copy number changes affecting metabolic genes in cancer, and more.
In blood samples from infected individuals, a seven-gene signature apparently distinguishes between bacterial and viral culprits, a distinction important to antibiotic use.
The company's approach investigates the utility of high-density lipoproteins as molecular markers for multiple diseases, starting with cardiovascular.
The genetic testing firm is developing a plan to drive market adoption of its PerioPredict test for inflammation-related genes.
The FDA considers Interleukin Genetics' PerioPredict test and the DNA-CardioCheck test to be medical devices.
Researchers link personality traits to the expression of certain inflammation-related genes.
Nebula Genomics will be auctioning George Church's genome as a nonfungible token, according to The Scientist.
Anthony Gregg, the outgoing president of the American College of Medical Genetics and Genomics, has resigned after using racially insensitive language.
Facebook has developed an artificial intelligence approach to predict how drugs interact in cells, New Scientist reports.
In PNAS this week: adaptations among high-altitude Mycobacterium tuberculosis, response of multiple myeloma cells to chemotherapy-induced stress, and more.